Arbutus Biopharma Corp Earnings Per Share (Diluted)
Arbutus Biopharma Corp (ABUS) reported Earnings Per Share (Diluted) of -$0.03 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-12
CAD/shares
| Period end | Earnings Per Share, Diluted 12 month |
|---|---|
| 2012-12-31 | 2.08 CAD/shares 20-F · filed 2013-03-27 |
| 2011-12-31 | -0.88 CAD/shares 20-F · filed 2013-03-27 |
| 2010-12-31 | -1.20 CAD/shares 20-F · filed 2013-03-27 |
USD/shares
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.03 10-Q · filed 2026-08-12 | $0.84 10-Q · filed 2026-08-12 | $0.82 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.79 derived: net income ÷ weighted average shares · filed 2026-08-12 | |
| 2026-03-31 | $0.87 10-Q · filed 2026-05-13 | $0.86 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.82 derived: net income ÷ weighted average shares · filed 2026-08-12 | $0.83 derived: net income ÷ weighted average shares · filed 2026-08-12 | |
| 2025-12-31 | -$0.02 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.06 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.05 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.17 10-K · filed 2026-03-23 | |
| 2025-09-30 | -$0.04 10-Q · filed 2025-11-13 | -$0.03 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.16 10-Q · filed 2025-11-13 | -$0.22 derived: net income ÷ weighted average shares · filed 2026-08-12 | |
| 2025-06-30 | $0.01 10-Q · filed 2026-08-12 | -$0.12 10-Q · filed 2026-08-12 | -$0.18 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-08-12 | |
| 2025-03-31 | -$0.13 10-Q · filed 2026-05-13 | -$0.19 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-08-12 | -$0.40 derived: net income ÷ weighted average shares · filed 2026-08-12 | |
| 2024-12-31 | -$0.07 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.28 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.38 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$0.10 10-Q · filed 2025-11-13 | -$0.21 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$0.31 10-Q · filed 2025-11-13 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-04-14 | |
| 2024-06-30 | -$0.11 10-Q · filed 2025-08-06 | -$0.21 10-Q · filed 2025-08-06 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-04-14 | |
| 2024-03-31 | -$0.10 10-Q · filed 2025-05-14 | -$0.22 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-04-14 | |
| 2023-12-31 | -$0.11 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-04-14 | -$0.44 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$0.12 10-Q · filed 2024-11-06 | -$0.22 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.32 10-Q · filed 2024-11-06 | -$0.46 derived: net income ÷ weighted average shares · filed 2024-11-06 | |
| 2023-06-30 | -$0.10 10-Q · filed 2024-08-08 | -$0.20 10-Q · filed 2024-08-08 | -$0.34 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.46 derived: net income ÷ weighted average shares · filed 2024-11-06 | |
| 2023-03-31 | -$0.10 10-Q · filed 2024-05-02 | -$0.24 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.36 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$0.45 derived: net income ÷ weighted average shares · filed 2024-11-06 | |
| 2022-12-31 | -$0.14 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$0.26 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$0.35 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$0.46 10-K · filed 2024-03-05 | |
| 2022-09-30 | -$0.12 10-Q · filed 2023-11-07 | -$0.21 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$0.32 10-Q · filed 2023-11-07 | -$0.47 derived: net income ÷ weighted average shares · filed 2023-11-07 | |
| 2022-06-30 | -$0.10 10-Q · filed 2023-08-03 | -$0.20 10-Q · filed 2023-08-03 | -$0.36 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$0.53 derived: net income ÷ weighted average shares · filed 2023-11-07 | |
| 2022-03-31 | -$0.11 10-Q · filed 2023-05-04 | -$0.26 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$0.44 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$0.63 derived: net income ÷ weighted average shares · filed 2023-11-07 | |
| 2021-12-31 | -$0.16 derived: net income ÷ weighted average shares · filed 2023-03-02 | -$0.34 derived: net income ÷ weighted average shares · filed 2023-03-02 | -$0.54 derived: net income ÷ weighted average shares · filed 2023-03-02 | -$0.83 10-K · filed 2023-03-02 | |
| 2021-09-30 | -$0.24 10-Q · filed 2022-11-09 | -$0.39 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$0.68 10-Q · filed 2022-11-09 | -$0.76 derived: net income ÷ weighted average shares · filed 2022-11-09 | |
| 2021-06-30 | -$0.23 10-Q · filed 2022-08-04 | -$0.44 10-Q · filed 2022-08-04 | -$0.57 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$0.80 derived: net income ÷ weighted average shares · filed 2022-11-09 | |
| 2021-03-31 | -$0.21 10-Q · filed 2022-05-05 | -$0.37 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$0.60 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$0.81 derived: net income ÷ weighted average shares · filed 2022-11-09 | |
| 2020-12-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2022-03-03 | -$0.43 derived: net income ÷ weighted average shares · filed 2022-03-03 | -$0.64 derived: net income ÷ weighted average shares · filed 2022-03-03 | -$1.00 10-K · filed 2022-03-03 | |
| 2020-09-30 | -$0.27 10-Q · filed 2021-11-04 | -$0.44 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$0.77 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$0.25 10-Q · filed 2021-08-05 | -$0.49 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | -$0.25 10-Q · filed 2021-05-05 | ||||
| 2019-06-30 | -$0.46 10-Q · filed 2019-08-05 | -$0.92 10-Q · filed 2019-08-05 | |||
| 2018-12-31 | -$0.38 10-K · filed 2019-03-07 | -$1.21 10-K · filed 2019-03-07 | |||
| 2018-09-30 | -$0.49 10-K · filed 2019-03-07 | ||||
| 2018-06-30 | $0.01 10-Q · filed 2019-08-05 | -$0.35 10-Q · filed 2019-08-05 | |||
| 2018-03-31 | -$0.36 10-K · filed 2019-03-07 | ||||
| 2017-12-31 | -$1.56 10-K · filed 2019-03-07 | ||||
| 2017-06-30 | -$0.33 10-Q · filed 2018-08-03 | -$0.68 10-Q · filed 2018-08-03 | |||
| 2016-12-31 | -$7.24 10-K · filed 2018-03-16 | ||||
| 2015-12-31 | -$1.38 10-K · filed 2018-03-16 | -$1.34 10-K · filed 2016-03-09 | |||
| 2014-12-31 | -$1.80 10-K · filed 2017-03-22 | ||||
| 2013-12-31 | -$0.92 10-K · filed 2016-03-09 | ||||
| 2012-12-31 | $2.07 10-K · filed 2015-03-13 | ||||
| 2011-12-31 | -$0.89 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |